News & Updates
Showing Paediatrics articles
Showing
Show Multimedia Only

Tralokinumab a promising treatment option in young people with moderate-to-severe AD
29 Apr 2023
Targeting interleukin (IL)-13 with tralokinumab monotherapy helps reduce disease activity in adolescents with moderate-to-severe atopic dermatitis (AD) with a low frequency of conjunctivitis throughout the treatment period, according to data from the phase III ECZTRA 6 trial.
29 Apr 2023







